Form 4: OptimizeRx COO Sells Shares for Tax Obligations

OptimizeRx Chief Operating Officer Brendan W. Merrell disposed of 712 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Brendan W. Merrell, Chief Operating Officer of OptimizeRx Corp (OPRX), reported a transaction on December 11, 2025.
• The transaction involved the disposition of 712 shares of OptimizeRx Common Stock at a price of $14.03 per share.
• These shares were withheld by the Issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.
• This withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934.
• Following this transaction, Mr. Merrell beneficially owns 26,496 shares of OptimizeRx Common Stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-planned.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction for tax purposes, which is neutral in sentiment and does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction related to compensation and tax obligations, and it does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by an executive to satisfy tax withholding obligations upon RSU vesting. Such transactions are common and pre-planned under Rule 10b5-1, providing no new material information about the company's operational performance, financial health, or future prospects. Therefore, it does not warrant a change in an existing investment recommendation; a 'hold' stance is appropriate as there's no new fundamental catalyst for 'buy' or 'sell'.

Keywords

OPRX, OptimizeRx, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, Brendan Merrell